II Robert C. Goeltz has sold stock and made no open-market buys since Mar 2017

Robert C. Goeltz II is the Chief Financial Officer of Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage biopharmaceutical company focused on oncology therapies, a role he assumed on August 1, 2020.( He continues in this position as of late 2025, recently selling shares including 6,552 on December 31, 2025, and 5,000 on November 26, 2025, while retaining significant ownership.(

Goeltz brings extensive finance and accounting experience from prior CFO roles at UNITY Biotechnology and CytomX Therapeutics, where he led both companies' IPOs.( He spent 11 years at Amgen, including as CFO of Onyx Pharmaceuticals post-acquisition, contributing to multiple oncology product launches, and earlier served as Director of Finance at Tularik and in EY's audit practice.( He holds an MBA from UCLA Anderson School of Management and a BBA from Emory University's Goizueta School of Business.(

Written by Perplexity from public sources.